Director Joseph Manko of Horton Capital Management was an insider that we came to know as a recurring Form 4 filer for Repro-Med. His filings helped shape the way we viewed Repro Med Systems (OOTC:REPR) as an investment, especially through the […]
Shares of Repro Med (OOTC:REPR) are little changed following the company’s 2016 second quarter results. We view this as an encouraging sign that the market may finally be ready to shrug off the lingering issue of the FDA Warning letter that […]
We believe that REPRO MED SYS INC (OOTC:REPR) can more than double from its recent trading price, but there are risks. The Company has been under a cloud since the FDA issued a warning letter concerning the company’s Freedom 60 Syringe […]
One of the best performing stocks in our portfolio over the last couple years just gave away 50% of its peak gains about three weeks ago, after the Food & Drug Administration (FDA) issued a warning letter asking the company […]
We have been highlighting the continuous open market purchases of Repro-Med Systems (OOTC:REPR) shares by Joseph Manko of Horton Capital Management the last several months. The last filing was on February 17,2016 which disclosed a purchase of 21,900 shares bringing Horton […]
GeoInvesting has been covering Repro-Med Systems (OOTC:REPR) for several years and in mid 2014, we explained that the company’s history of growing revenues would eventually garner investor attention. Yesterday, the stock’s price matched its 52-week high, which also happens to be the […]
Right now, we have two stocks trading around $0.50 that are gaining momentum and that we believe are on their way to $1. Fueled by insider buying, company buybacks, low valuations and the current thawing of the micro-cap universe, the […]
The GeoTeam has been monitoring developments that might impact REPRO MED SYS INC (OOTC:REPR) and its flagship product, the FREEDOM60 pump (mechanical infusion pump system) and related needle sets used to deliver medication to primary immune deficiency patients. We noted that […]